Format

Send to

Choose Destination
Hell J Nucl Med. 2017 Sep-Dec;20(3):251-253. doi: 10.1967/s002449910611. Epub 2017 Nov 27.

Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib.

Author information

1
Medical PET Group-Biological Imaging, Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, D-69210, Heidelberg, Germany. christosâ‚‹saxpe @yahoo.gr, c. sachpekidis@dkfz.de.

Abstract

Combination therapies for the treatment of metastatic melanoma are a matter of debate nowadays. We report on a stage IV metastatic melanoma patient with the BRAF V600 mutation and a large tumor burden initially treated with two cycles of ipilimumab. Due to dramatic disease progression, demonstrated on interim 18F-FDG PET/CT, vemurafenib was added in the patient's therapeutical scheme. After completion of the concurrent ipilimumab and vemurafenib administration, a third 18F-FDG PET/CT showed an impressive metabolic remission of the metastatic disease, reflecting the potential role of the modality in treatment response evaluation of melanoma patients receiving combination therapies.

PMID:
29177265
DOI:
10.1967/s002449910611
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for P.Ziti and Co
Loading ...
Support Center